Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Arecor appoints new commercial manager to Tetris subsidiary
(Sharecast News) - Arecor Therapeutics announced the appointment of Dr Helen Parris as senior vice president and commercial and general manager of its subsidiary Tetris Pharma on Wednesday. The AIM-traded firm said Dr Parris would assume her new role on 15 January.
It said that with more than two decades of experience in scientific, commercial, and government affairs within the international biopharmaceutical sector, Dr Parris would bring a wealth of expertise to her new position.
The board said she has a track record of launching transformative products and shaping markets while working with major pharmaceutical and biotechnology companies.
Before her appointment at Tetris Pharma, Dr Parris was the general manager for the UK, Netherlands, and the Nordics at Albireo Pharma.
Ipsen acquired the company in March last year, and Dr Parris reportedly played a pivotal role in establishing and developing the regional affiliate, as well as successfully launching its first product to market.
Dr Parris also had a notable history at Gilead, where she held various positions, including executive director of EMEA and global affairs regional lead.
During her tenure at Gilead, she played a crucial role in expanding patient access to treatment and spearheaded the launch of several groundbreaking drugs.
Her contributions included the development of critical launch strategies and the exploration of new commercial opportunities.
Arecor said Dr Parris holds a BSc in Biology from York University, a PhD from Leeds University, and an MBA from Henley Management College.
"Helen's proven track record in bringing products to market and growing sales will be key as we continue the roll-out of Ogluo across the UK and Europe," said chief executive officer Sarah Howell.
"Ogluo is an important treatment for people with diabetes and their caregivers that can provide them with the confidence to manage severe hypoglycaemic events and, under Helen's leadership, Tetris Pharma is even better positioned for the continued adoption of this key product in a £100m market.
"Not only will this deliver a revenue stream but a successful commercial distribution platform through Tetris Pharma is highly complementary to our existing specialty hospital products business and has significant growth potential, providing Arecor with the capability to take selected products to market in the UK and Europe."
At 1021 GMT, shares in Arecor Therapeutics were down 0.83% at 178.5p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.